{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-008518","form_type":"8-K","ticker":"BFRG","cik":"0001829247","company_name":"BullFrog AI Holdings, Inc.","filed_at":"2025-02-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.130831+00:00","generated_at":"2026-05-26T02:32:57.237573+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"confidence":"high","headline":"Bullfrog AI enters collaboration with Eleison to optimize Phase 3 pancreatic cancer trial","bullets":["Collaboration announced Feb 27, 2025; Bullfrog AI to apply bfLEAP platform to Eleison's glufosfamide Phase 3 trial.","Bullfrog Data Networks will analyze safety signals and extract predictive biomarkers from prior and ongoing studies.","Eleison's ongoing glufosfamide Phase 3 trial targets second-line pancreatic cancer; expected completion in 2027.","Financial terms of the agreement were not disclosed.","Partnership also covers Eleison's pipeline programs ILC (lung cancer) and DBD (brain cancers)."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-008518","json":"https://secwatch.observer/filing/0001493152-25-008518.json","markdown":"https://secwatch.observer/filing/0001493152-25-008518.md","text":"https://secwatch.observer/filing/0001493152-25-008518.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1829247/000149315225008518/0001493152-25-008518-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1829247/000149315225008518/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T02:32:57.237573+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}